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The increasing realization of the involvement of lectin-glycan recognition in (patho)physiological processes
inspires envisioning therapeutic intervention by high-avidity/speciﬁcity blocking reagents. Synthetic
glycoclusters are proving to have potential for becoming such inhibitors but the commonly used assays
have their drawbacks to predict in vivo eﬃcacy. They do not represent the natural complexity of (i) cell
types and (ii) spatial and structural complexity of glycoconjugate representation. Moreover, testing lectins
in mixtures, as present in situ, remains a major challenge, giving direction to this work. Using a toolbox
with four lectins and six bi- to tetravalent glycoclusters bearing the cognate sugar in a model study, we
here document the eﬃcient and versatile application of tissue sections (from murine jejunum as the
model) as a platform for routine and systematic glycocluster testing without commonly encountered
limitations. The nature of glycocluster structure, especially core and valency, and of protein features, i.e.
architecture, ﬁne-speciﬁcity and valency, are shown to have an inﬂuence, as cell types can diﬀer in
response proﬁles. Proceeding from light microscopy to monitoring by ﬂuorescence microscopy enables
grading of glycocluster activity on individual lectins tested in mixtures. This work provides a robust tool
for testing glycoclusters prior to considering in vivo experiments.Introduction
The realization of the unsurpassed capacity of glycans to store
biological information in a minimum of space enables eluci-
dating the chain of molecular events, from oligosaccharide
synthesis and establishing the spatial aspects of their presen-
tation on glycoconjugates and membranes to actual cellular
eﬀects, to become a staple of current research.1 Shaping
a paradigm for this area, these eﬀorts disclosed that reading of
sugar-encoded messages by tissue lectins is an eﬃcient means
to facilitate molecular bridging. When occurring between cells
and also between cells and the extracellular matrix (in trans), it
can lead to adhesion.2–5 Cross-linking of constituents withinFaculty of Veterinary Medicine,
erina¨rstr. 13, 80539 Munich, Germany
Ireland Galway, University Road, Galway,
ie
ryology, Faculty of Veterinary Medicine,
erina¨rstr. 13, 80539 Munich, Germany
of Surgeons of Ireland (RCSI), 123 St.
tion (ESI) available. See DOI:
5a membrane (in cis) will form so-called glycoconjugate-lectin
lattices that can trigger ensuing signalling.6–10 In each case,
the intimate interplay of structural and topological parameters
on both sides minimises stabilisation of random contacts, thus
underlying the functional pairing of a lectin with not just any
glycoconjugate, but with its matching counterreceptor(s).
Hereby, glycan-encoded messages are read and then translated
into particular post-binding responses. This theme of mutually
specic protein(lectin)–glycan recognition appears to have
a broad physiological signicance.11–14
Naturally, these emerging insights give strong incentive to
search for compounds that will block this type of interaction if
clinically unfavourable, andmimetics of polyvalent glycans termed
glycoclusters have already been found to be particularly active.15–18
Besides their design and synthesis, a central challenge to master
toward a prospect of biomedical application is the experimental
set-up tomeasure inhibitory capacity. Optimally, it should come as
closely as possible to the in vivo situation (in animals and man)
with its diversity on the levels of glycans presented by glyco-
conjugates19–22 and of cell types, at the same time allowing for wide-
scale testing in a robust manner with a clear read-out. The exper-
imental approach to meet this challenge presented herein is
a logical extension of classical lectin histochemistry.This journal is © The Royal Society of Chemistry 2018
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View Article OnlineGiven their binding to certain glycans, labelled lectins from
plants have acquired popularity as reliable and sensitive tools to
map the distribution of their ligands in sections of any type of
tissue.23–28 What commonly is a routine specicity control, i.e.
the inhibition of lectin binding to cells in a tissue section by
a sugar (mono- to oligosaccharide),24,27,29 has the attractive
potential to be adapted to an assay for glycocluster eﬃcacy,
fullling the requirements for physiological relevance listed
above. By assembling a toolbox of (i) seven mono- to tetravalent
N-acetyl-D-galactosamine (GalNAc)-presenting compounds and
(ii) four lectins that share nominal specicity to a mono-
saccharide (GalNAc), among them a human protein that binds
to GalNAc presented by mucins (for an overview on mucins,
please see30), and then working with these two sets to system-
atically monitor staining and intensity proles in sections of
a model tissue, i.e. murine jejunum, by light microscopy, we
provide the proof-of-principle case study to document this
assay's applicability. In fact, it opens the route to activity
grading for any compound and any lectin on standard tissue
specimens, oﬀering the possibility for having natural binding
partners act on both sides. Considering the occurrence of
endogenous lectins in mixtures in vivo, a highly relevant situa-
tion for glycocluster testing, we also succeeded in adapting the
assay to determine the individual behaviour of lectins when
tested in combination. Toward this end uorescence micros-
copy at diﬀerent wavelengths was performed.Fig. 1 Structures of glycoclusters 1–6 (with GalNAc as headgroup) and 8,
derivative 7.
This journal is © The Royal Society of Chemistry 2018Results and discussion
The toolbox: 1. glycoclusters and control compounds
The panel of glycocluster-based inhibitors comprises six bi- to
tetravalent compounds (1–6), all presenting GalNAc with a-
anomeric linkages as thioglycosides (Fig. 1). The parameters of
scaﬀold structure and valency are independently varied within
this group. Compounds 3 and 5 diﬀer in valency but share
scaﬀold structure; the three pairs of compounds, i.e. 1 and 6, 2
and 3 as well as 4 and 5, share valency but diﬀer in scaﬀold
structure. The group of test compounds is completed by adding
an the a-GalNAc derivative 7 and two control compounds (8, 9)
with the same bulky cores of compound 5 and 6, but presenting
a non-cognate sugar, GlcNAc.
The synthesis of glycoclusters 1, 2 and 5 has been described
previously.31 The route to obtaining trivalent compound 3 with
its tetraphenylethylene core is shown in Scheme 1. It
commenced from the tetraphenylethylene derivative 10.31
Monoacetylation using acetic anhydride in limiting quantity
(0.7 equiv.) followed by propargylation of the remaining
phenols gave 11. Next, the copper-catalysed azide–alkyne
cycloaddition (CuAAC) between the known azide 12 was per-
formed, followed by deacetylation of the product to give 3, in
which three of four positions are occupied by a sugar headgroup
(in comparison to tetravalent 5).9 (with GlcNAc) as well as of themonovalent a-anomeric thioglycoside
RSC Adv., 2018, 8, 28716–28735 | 28717
Scheme 1 Synthesis of 3.
Scheme 2 Synthesis of 4.
28718 | RSC Adv., 2018, 8, 28716–28735 This journal is © The Royal Society of Chemistry 2018
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Scheme 3 Synthesis of 6.
Scheme 4 Synthesis of 7.
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View Article OnlineThe synthesis of compound 4, using conjugation sites on D-
mannitol to implement tetravalency, started with 13 and is
summarised in Scheme 2.32 Tetrapropargylation was followed
by removal of the acetonide group, resulting in 14. Next, CuAAC
with 12 and subsequent deacetylation generated 4.
The bivalent compound 6 was prepared as summarised in
Scheme 3. Firstly, 1231 was deacetylated, and then, with heating,
the CuAAC reaction using dialkyne 1633 produced 6. The di-
alkyne 16 was prepared in three steps from known 15.34
Following the preparation of the GalNAc-presenting glyco-
clusters 1–6, a monovalent a-anomeric GalNAc derivative was
prepared as a probe to measure anomeric preference of lectinScheme 5 Synthesis of 8.
This journal is © The Royal Society of Chemistry 2018binding, when set in relation to results with free GalNAc as
standard. In detail, methyl a-thioglycoside 7 was obtained in
two steps from glycosyl thiol 1735 (Scheme 4). In addition to this
panel of compounds with cognate sugar, an N-acetyl-D-glucos-
amine (GlcNAc)-bearing bivalent analogue of compound 6 was
synthesized. Its availability allows to perform controls that
exclude interaction of glycoclusters with bulky core with lectins
by carbohydrate-independent molecular stickiness. This biva-
lent GlcNAc derivative 833 was prepared via 18–20,33 as sum-
marised in Scheme 5.
As further control compound for specicity testing, we
included compound 9, a GlcNAc-presenting analogue of
compound 5. It had proven to be bioactive as potent inhibitor of
two plant lectins with this monosaccharide specicity, i.e. WGA
and GSA-II,36 here served as additional control to trace
carbohydrate-independent signal generation.
In order to characterize spatial aspects of valency on the
tetraphenylethylene, D-mannitol and BF2-azadipyrromethene
cores, distances between the hydroxyl groups were calculated by
molecular modelling based on crystal structures obtained fromRSC Adv., 2018, 8, 28716–28735 | 28719
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View Article Onlinethe Cambridge Crystallographic Database in three cases34,37
(Fig. 2). In fact, the nature of the core will constrain the
maximum spacing possible between GalNAc residues in the
most extended conformations. As shown in Fig. 3, these
distances in the tetraphenylethylene derivative 3 can likely be
larger than for the D-mannitol-based 4 (29 A˚ vs. 20 A˚ in Fig. 3).
The BF2-azadipyrromethene scaﬀold facilitates a spacing that
could extend to 28 A˚ between its two GalNAc residues, again
longer than for the D-mannitol derivative 4 (Fig. 3) and alsoFig. 2 CPK models of the core scaﬀolds tetraphenylethylene (a),
D-mannitol (b), and BF2-azadipyrromethene (c), on which GalNAc-
containing glycoclusters studied herein were built. The distances
between O-l atoms are shown; those in D-mannitol are between O
atoms at C-1, -2, -5 and -6. The models are based on data derived for
crystal structures obtained from the Cambridge Crystallographic
Database.37 The CPK models were generated in Macromodel (http://
www.schrodinger.com).
28720 | RSC Adv., 2018, 8, 28716–28735longer than for 1, the latter estimated at 22 A˚ in our earlier
work.31 The D-mannitol- and tetraphenylethylene-based glyco-
clusters can thus be considered as cornerstones for the spec-
trum of degree of compactness and of distance between sugar
headgroups.
In summary, the panel of glycoclusters covers diﬀerent
aspects of valency and inter-headgroup spacing for the same
sugar used as lectin ligand. The eﬀect of a glycocluster on this
activity can likely vary between lectins. As consequence, it will
best be measured, if GalNAc-specic receptors with diﬀerent
characteristics in terms of spatial presentation of contact sites
for the sugar are selected. Of note, spatial valency on both sides
of the recognition process can cooperate in situ so that its
complementarity can result in a Lego-like association with
benecial eﬀects on aﬃnity by lowering oﬀ-rates38,39 and theFig. 3 CPK models of selected conformers of compounds 3 (a), 4 (b)
and 6 (c). Distances between anomeric carbons of the GalNAc residues
presented by each core in these conformers are shown. The CPK
models were built in Macromodel.
This journal is © The Royal Society of Chemistry 2018
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View Article Onlineinhibitory potency.40,41 Besides spatial aspects, the ne-
specicities of lectins may well diﬀer. Since more than
a dozen folds with diverse molecular architecture and quater-
nary structure have developed the capacity to act as lectins,
“lectins considered ‘identical’ in terms of monosaccharide
specicity possess the ability to recognize ne diﬀerences in
more complex structures”42 and protein engineering facilitates
custom-made tailoring, this is possible: the group of selected
lectins is presented in the next section.
The toolbox: 2. lectins
The panel of lectins comprises plant, invertebrate and human
proteins that diﬀer in ne-specicity and valency (Table 1). In
detail, two tetravalent leguminous lectins (Dolichos biorus
agglutinin (DBA) and soybean agglutinin (SBA)), a hexameric
lectin from the albumen gland of the edible (or vineyard) snail
(Helix pomatia (HPA)) and the human macrophage galactose
(-binding C)-type lectin (MGL) in two engineered forms, i.e. asTable 1 Molecular characteristics of the four tested lectins
Acronym Quaternary structure (number of binding sites)a
DBA Tetramer (4)
SBA Tetramer (4)
HPA Hexamer (6)
MGL
CRD monomer (1)
(CRD + stalk) trimer (3)
a Estimated/measured distances between contact sites for the ligand: DBA,
100 A˚ apart, each formed by a trimer with inter- contact site distance of 2
This journal is © The Royal Society of Chemistry 2018free monomeric carbohydrate recognition domain (CRD) and as
CRD extended by the a-helical coiled-coil stalk of the trans-
membrane receptor that confers its trimerisation. Table 1
presents schemes of the quaternary structures and listings of
specicity proles (for details on ne-specicity, please see;43–54
for details on structural aspects, please see48,50,55–60). As docu-
mented in this table, the relative degrees of aﬃnity to natural
GalNAc-containing glycans are not identical. As a consequence,
extents of cell binding are likely to diﬀer for these lectins, and
this has for example been indeed revealed by array analysis in
the cases of Chinese hamster ovary (CHO) cells and three of its
glycosylation mutants (Lec1, Lec2, Lec8) for DBA, SBA and
HPA.61,62
In summary, the panel of lectins covers ve proteins with
well-characterised biochemical characteristics (Table 1). A
human lectin is deliberately included to document feasibility to
work with endogenous (tissue) lectins. The eﬀect of glycocluster
presence on ligand binding in a lectin histochemical modelGlycoligand
a-GalNAc, GalNAca3GalNAca3Galb4Galb4Glc >
A-tetrasaccharide; GalNAca4Gal/GalNAcb3Gal
(P-like)/GalNacb4Gal (asialo CAD)/T(F) disaccharide
only weakly active
a/b-GalNAc, GalNAca3Gal(b6Glc); GalNAca4Gal,
GalNAcb3/4Gal more active than
Tn antigen, a2fucosylation of A-disaccharide
reduces activity, T(F) disaccharide only weakly active
a-GalNAc > b-GalNAc/a-GlcNAc, GalNAca3GalNAc/
GalNAca3/4Gal/GalNAcb4Gal as active as
Tn (GalNAcb3 only weakly active), (s/su)T(F)
antigens active, GlcNAca3/4-terminated LacNAc;
highly potent precipitinogen/sensor for low-density
presentation of Tn antigen
Tn and s/suTn antigens (Tn presentation by Tyr active),
core 5/6 mucin-type O-glycans, b4-linked GalNAc
in LacdiNAc or in chains of GD2/GM2 (not GD3/GM3)
gangliosides
SBA about 55 A˚ or 68 A˚; HPA, hexamer arranged as two at surfaces about
5 A˚; MGL trimer about 50 A˚.
RSC Adv., 2018, 8, 28716–28735 | 28721
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View Article Onlinestudy will best be measured in sections of a tissue, to which all
tested proteins can bind, and this then yielding strong signals,
most preferably for more than a single cell type. Known binding
properties of gastrointestinal tissue to this group of proteins
when used as histochemical probes63–67 guided us to select
murine jejunum.The toolbox: 3. murine jejunum
Main aspects of the structure of jejunal villi and crypts (of Lie-
berkuehn) are illustrated in Fig. 4, where a schematic drawing is
combined with microphotographs of sections at two levels ofFig. 4 Illustration of the morphological aspects in a longitudinal section
colour coding andmicrophotographs at two levels of magniﬁcation. Repr
brush border) and also crypt-associated cells (incl. Paneth cells, enteroe
cells) at the basis of the crypts (cr) were marked by colour-coded circle
28722 | RSC Adv., 2018, 8, 28716–28735magnication. Running the lectin histochemical protocol
without the incubation step with a labelled sensor for GalNAc-
containing glycoconjugates led to no generation of a signal,
that is to no change in appearance of the haemalaun-stained
tissue (Fig. 5a). If generated, the signals will thus be entirely
dependent on the presence of a labelled lectin.
In order to record stainings for each protein and to deter-
mine optimal conditions for applying glycoclusters as inhibi-
tors for lectin binding systematic titrations of lectin
concentrations were performed for each lectin. Staining was
routinely assessed as the intensity of the signal and as
percentage of positive cells. An example for the correlationof ﬁxed murine jejunum by a combination of schematic drawings with
esentative regions in intestinal villi (en, enterocytes; go, goblet cells; bb,
ndocrine cells, precursors of enterocytes and goblet cells and mitotic
s, these areas shown in enlarged representation.
This journal is © The Royal Society of Chemistry 2018
Fig. 5 Staining proﬁles by biotinylated DBA, SBA, HPA and the two forms of MGL in longitudinal sections through ﬁxed murine jejunum.
Incubations were done with concentrations of lectins that lead to a strong signal with minimal background (100% level). (a) Negative control by
omission of the incubation step with ﬁrst-step reagent (labelled lectin) with no evidence for lectin-independent signal generation (blank value as
shown in Fig. 4) (b and c) strong reactivity for DBA (b) and SBA (c) was found in the brush border of surface enterocytes from intestinal villi
(arrowheads), goblet cells (arrows) and in crypt-associated cells, especially in the deep parts of the crypts (asterisks). (d) Binding of biotinylated
HPA was detected supranuclearly in surface enterocytes from intestinal villi (arrowheads) (high-level magniﬁcation of this region is shown in an
inserted circle above the respective area) and in the deep parts of the crypts (asterisks). (e and f) MGL-dependent positivity (similar for the two
protein forms) in crypt-associated cells, most prominently in the crypts' deep parts (asterisks) and comparatively weaker in the cytoplasm of
surface enterocytes from intestinal villi. No staining was seen in the brush border (arrowheads; higher magniﬁcation is shown in an inserted circle
above the respective area). Insets in panels b to e show extent of blocking lectin binding by co-incubation of the lectins with free GalNAc at
200mM. Concentration of biotinylated lectins usedwere 1 mgmL1 for DBA, 3 mgmL1 for SBA, 1.5 mg for HPA and 4 mgmL1 for both engineered
forms of MGL. Scale bars are 20 mm (a–f) and 5 mm (circles in d and e).
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View Article Onlinebetween lectin concentration and staining intensity/number of
positive cells is shown in ESI Fig. S1† for SBA. For each lectin,
signal increases reached plateau values, revealing that binding
was saturable (for details on titration ranges, please see Exper-
imental section). These titration series thus led to dening
experimental conditions to reach signals of strong intensity as
starting point for testing glycoclusters.
The signals were present in diﬀerent regions of the tissue
sections. As summarized in Table 2, surface enterocytes and
crypt-associated cells together with goblet cells, here primarilyThis journal is © The Royal Society of Chemistry 2018apically targeting the mucus, are the main sites for lectin
binding. Binding to intestinal villi exhibited diﬀerences,
whereas signal intensity of crypt-associated cells was rather
uniform (Table 2). Exemplary microphotographs illustrate the
staining prole for each type of lectin (Fig. 5b–f). They also
document (by insets) reduction of staining by inhibition of
lectin binding by the cognate monosaccharide used at high
concentration (Fig. 5b–f). In sum, staining was dependent on
the lectin, saturable, inhibitable by cognate sugar and diﬀerent
with respect to cell and lectin types.RSC Adv., 2018, 8, 28716–28735 | 28723
Table 2 Binding of lectins to sections of murine jejunum
DBA SBA HPA
MGL
CRD CRD + stalk
Intestinal villi
Surface enterocytes
Cytoplasm +(3)c +(3)  +++(8) +++(8)
Subapical cytoplasm +(3) +(3)  +++(8) +++(8)
Supranuclear cytoplasm  ++(4) ++++(8) +++(8) +++(8)
Brush (striated) border ++++(8) ++++(8) +/(2)  
Goblet cells ++++(8) ++++(8)   
Lamina propria
Immune cells     
Fibroblasts     
Smooth muscle cells     
Endothelial cellsa     
Crypts of Lieberkuehn
Crypt-associated cellsb
Cytoplasm ++++(8) ++++(8) ++++(8) ++++(8) ++++(8)
Subapical cytoplasm ++++(8) ++++(8) ++++(8) ++++(8) ++++(8)
Supranuclear cytoplasm ++++(8) ++++(8) ++++(8) ++++(8) ++++(8)
Goblet cells ++++(8) ++++(8)   
a Capillaries of the lamina propria. b Incl. Paneth cells, enteroendocrine cells, precursor of enterocytes and goblet cells, and mitotic cells. c For
details on categories of semiquantitative assessments in terms of intensity of lectin-dependent signal ( to ++++)/number of positive cells (0–
100%), please see section on lectin histochemistry in Experimental.
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View Article OnlineHaving equipped the toolbox with panels of synthetic gly-
coclusters and lectins, also selected a tissue for this model
study, whose sections will present carbohydrate-inhibitable
signals in distinct cell types, and dened parameters of the
histochemical protocol, systematic titrations with the panel of
glycocompounds shown in Scheme 1 were performed at
a certain lectin concentration to determine relative activities in
each case for each type of lectin. Specimens of four animals
were processed, in each case at least with duplicates obtained as
serial sections in parallel and examined independently by two
observers.Glycoclusters as inhibitors of tissue staining by lectins:
1. light microscopy
The systematic titrations of glycocompound concentration at
the constant concentration of a lectin revealed bioactivity of
GalNAc, as free monosaccharide or as part of glycoclusters. In
other words, lectin binding to GalNAc-containing glycans of
cellular glycoconjugates was impaired by the presence of Gal-
NAc in the solution, as free monosaccharide or derivative
thereof (compound 7) or as part of a glycocluster (compounds
1–6), in a concentration-dependent manner, as seen in the
insets of Fig. 5b–f. The extent of distinctly non-uniform
responses depended on the nature of the test compound and
the lectin. Exemplary illustrations of how staining proles are
aﬀected by presence of increasing concentrations of the inhib-
itor are presented for the pairs 3/DBA and 2/SBA (Fig. 6). As
shown in this gure, staining (in terms of signal intensity and
percentage of positive cells) was reduced by the presence of28724 | RSC Adv., 2018, 8, 28716–28735a GalNAc-presenting compounds. Conjugation of the cognate
sugar did obviously not impair its lectin-binding activity.
Expressed in terms of the concentration that caused 50%
inhibition (IC50) of signal intensity and cell positivity, respective
values for inhibitory activity are compiled for each compound
and tissue constituent in Table 3.
This summary teaches a series of lessons, starting with the
broad range of concentrations of sugar needed to diminish the
signal within this lectin panel. Proceeding from the arrest
induced by the a-S-glycoside 7, the chemical design of bi- to
tetravalent glycoclusters with a-GalNAc as headgroup is
revealed to be capable to lead to up to marked increases (up to
10 000 fold for MGL) of inhibitory capacity of GalNAc (Table 3).
Graphically, this point is underscored by comparatively doc-
umenting staining proles by the ve labelled proteins in the
presence of a constant concentration of tetravalent compound 5
and of bivalent compound 6 (Fig. 7). Since these two types of
core are especially bulky and prone to engage in hydrophobic
interactions, we tested b-GlcNAc-presenting homologues 8 and
9 to exclude the concern of carbohydrate-independent (non-
specic) binding. By substituting cognate GalNAc by its non-
cognate epimer GlcNAc, the resulting glycoclusters should
lose their capacity to inhibit binding of the lectins. As shown in
ESI Fig. S2,† the two compounds with this non-cognate sugar
have no inhibitory capacity.
Considering inhibitory activity, compound core structure
(for 1 vs. 6, 2 vs. 3 and 4 vs. 5), valency of the core and the
protein, also – but less so – valency of the protein in the two
diﬀerent forms of MGL appear to matter. Already bivalencyThis journal is © The Royal Society of Chemistry 2018
Fig. 6 Staining proﬁles by biotinylated DBA (a–d, arrowheads mark staining of goblet cells in villi) and SBA (e–h, arrows mark staining of crypt-
associated cells) in sections of ﬁxedmurine jejunum in the presence of increasing concentrations of cognate sugar (GalNAc) assessed in terms of
staining intensity (percentage of positive cells). The signal for DBA binding remained at the 100% level in the presence of 1 mMGalNAc presented
by compound 3 (a). When raising the sugar concentration stepwisely to 2 mM (b), 5 mM (c) and 10 mM (d), respectively, scaﬀold-presented
GalNAc (by compound 3) led to a notable degree of inhibition. SBA-dependent staining intensity and percentage of positive cells were seen to be
reduced more strongly at comparatively low concentrations of 0.001 mM (e), 0.05 mM (f), 0.1 mM (g) and 0.5 mM (h) of GalNAc-presenting
compound 2. Semiquantitative grading of staining intensity/percentage of positive cells is given in the rectangular box in the top-right area of
each microphotograph (v, surface enterocytes of intestinal villi; c, crypt-associated cells). Intensity of staining in sections is grouped into the
following categories: , no staining; (+), weak but signiﬁcant staining; ++ medium staining; +++, strong staining; ++++, very strong staining.
Percentage of positive cells is expressed in the following eight categories: (1) 0% (no positive cells), (2) < 5% (few positive cells), (3) 5–20%, (4)
21–40%, (5) 41–60%, (6) 61–80%, (7) 81–95% (few negative cells), (8) up to 100% (no negative cells). Concentration of biotinylated DBA/SBA:
1 mg mL1/3 mg mL1. Scale bars are 20 mm.
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View Article Onlinebrings about marked activity increases related to free GalNAc, as
for example the case of HPA blocking by compound 6 (but not 1)
attests. Overall, structural design of each type of glycocluster
accounts for diﬀerences in inhibitory potency on this hex-
avalent lectin (Table 3), indicative of the assumed mutual
complementarity. The mechanism(s) underlying the inhibition
of lectin binding will involve intra- and/or intermolecular
bridging, and, “depending on the size and geometry of proteins
and ligands, several binding modes may be possible and
eﬀective in parallel and in varying proportions.”68
The comparison of the data sets for the two leguminous
lectins discloses large disparities in aﬃnity already at the
monosaccharide level, fully in line with published data.43,45
These results emphasise that simple extrapolations between
related proteins are not possible, a strong caveat when
considering activity on members of families of tissue lectinsThis journal is © The Royal Society of Chemistry 2018such as C-type lectins or galectins. Since they are found to be
co-expressed in tissues by immunohistochemical monitoring
with non-cross-reactive antibodies, as for example accom-
plished for galectins,69–71 the individual testing of each
protein will in the rst step be mandatory, as documented
herein, then taking the methodological step to testing lectins
in mixtures.
In addition to glycocluster and lectin parameters, the assay
also provides information on cell types. As shown in Fig. 7
(listed in more detail in Table 3), the reactivity proles of two
cell populations, i.e. surface enterocytes and crypt-associated
cells, exhibit disparities. In common binding assays using
a certain glycoprotein as ligand, occurrence of such varying
response proles would remain undetectable, because cell
type-dependent glycome diﬀerences are not established.
Having glycome complexity present in this assay is thusRSC Adv., 2018, 8, 28716–28735 | 28725
Table 3 IC50-values of glycoclusters (given in mM based on GalNAc) and the cognate monosaccharide in lectin histochemical assays with
biotinylated lectins applied to sections of ﬁxed murine jejunum
Compound/cell type DBA SBA HPA
MGL
CRD CRD + stalk
1
Surface enterocytes n.i.a 10.0 (0.05)b >10.0 (<0.5) >20.0 (<1.25) >20.0 (<1.25)
Crypt-associated cells n.i.a 20.0 (0.1) >20.0 (<0.25) >20.0 (<2.5) >20.0 (<2.5)
2
Surface enterocytes 1.0 (25) 0.02/0.01 (50/100) 5.0 (1.0) 1.0 (25) 1.0 (25)
Crypt-associated cells 2.0 (25) 0.01 (200) 5.0 (1.0) 1.0 (50) 2.0 (25)
3
Surface enterocytes 2.0 (12.5) 0.005/0.002 (200/500) 0.1/0.05 (50/100) 0.05 (500) 0.1 (250)
Crypt-associated cells 5.0 (10) 0.005/0.002 (200/500) 0.5/0.2 (10/25) 0.05 (1000) 0.1 (500)
4
Surface enterocytes 1.0 (25) 0.005 (200) 1.0 (5.0) 0.05/0.02 (500/1250) 0.1/0.05 (250/500)
Crypt-associated cells 5.0 (5) 0.01 (200) 5.0 (1.0) 0.05/0.02 (1000/2500) 0.1/0.05 (500/1000)
5
Surface enterocytes 2.0 (12.5) 0.001/0.0005 (1000/2000) 0.05/0.02 (100/250) 0.01/0.005 (2500/5000) 0.005 (5000)
Crypt-associated cells 5.0 (10) 0.001 (2000) 0.02 (250) 0.01/0.005 (5000/10 000) 0.005/0.002
(10 000/25 000)
6
Surface enterocytes 20 (1.4) 0.1 (10) 0.1 (50) 0.2 (125) 0.1 (250)
Crypt-associated cells >20 (<2.5) 0.2 (10) 0.2 (25) 0.2 (250) 0.2/0.1 (250/500)
7
Surface enterocytes 20 (1.25) 0.02 (50) 0.5 (10.0) 5.0 (5) 10.0 (2.5)
Crypt-associated cells >20 (<2.5) 0.05 (40) 2.0 (2.5) 1.0 (50) 2.0 (25)
D-GalNAc
Surface enterocytes 25.0 1.0 5.0 25.0 25.0
Crypt-associated cells 50.0 2.0 5.0 50.0 50.0
a n.i.: not inhibitory; tested up to 20 mM. b Numbers in parentheses denote relative inhibitory potency using activitiy of free GalNAc as standard set
to 1.
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View Article Onlinecertainly an advantage, and the detection of cell type-
dependent disparities underscores the merit of this system.
What is more, tissue sections as test platform also oﬀer
a means to address the mentioned issue that tissue lectins can
be co-expressed in situ.
Of note, these lectins can exhibit overlapping carbohy-
drate specicities, as known from several lectin families.72,73
When co-expressed, they can obviously cooperate with addi-
tive or antagonistic impact on the functional outcome, as
(rst) case studies on galectins are revealing.74–77 Thus, being
able to determine binding proles of individual lectins and
eﬀect of a glycocluster on them at the same time in mixtures
of tissue lectins would be ideal, and there is a histochemical
way to accomplish this. Diﬀerent modes of protein labelling
facilitate to perform these measurements. In detail,
diﬀerent uorescent dyes can be used for protein labelling
(SBA, MGL) or a two-step procedure with a uorescent probe
to detect biotinylated proteins (DBA, HPA) in the tissue is
performed.28726 | RSC Adv., 2018, 8, 28716–28735Glycoclusters as inhibitors of tissue staining by lectins:
2. uorescence microscopy
Both procedures led to the typical staining proles of the
tested lectins, as shown for each lectin in ESI Fig. S3† together
with the essential specicity control, here presence of
compound 5. The comparison of the staining distribution in
the absence (panels a–d) and presence of compound 5 (panels
e–h) unveils a rather similar signal pattern, as obtained by
processing with light microscopical assessment. This
comparative analysis built the basis to proceed to perform
double and triple staining.
When testing mixtures, competition between lectins for
binding sites can ensue, as is the case (patho)physiologically. The
resulting staining proles then inform about the extent of this
competition. An example of staining aer testing a binary
mixture is presented in ESI Fig. S4† in the case of the two legu-
minous lectins. Presentation of the microphotographs recorded
in each channel and of the (photo)merged les documents the
merits of this procedure, in the absence of inhibitor (Fig. S4a–c†)This journal is © The Royal Society of Chemistry 2018
Fig. 7 Staining proﬁles by the four labelled lectins in longitudinal sections of ﬁxedmouse jejunum in the presence of a constant concentration of
cognate sugar (0.02 mM in compound 5; arrows mark staining of the brush border). a–e Signal intensity and percentage of positive cells
remained at the 100% level after applying biotinylated DBA (a), whereas both parameters dropped to zero levels when using biotinylated SBA (b).
This set-up reduced HPA-dependent binding to nearly 50% level (c). Binding of both forms of MGL was strongly inhibited (d and e). The
concentration of 0.2mMGalNAc presented by the bivalent compound 6 (f–j; arrowheadsmark staining of goblet cells) had a slight eﬀect on DBA
staining in surface enterocytes (f). This concentration and this type of GalNAc presentation signiﬁcantly reduced the intensity of the staining
patterns of the other lectins applied (for details, please see Table 3). Binding of SBA (g) and HPA (h) was subject to a reduction by about 50% in
surface enterocytes of intestinal villi (SBA: brush border, HPA: supranuclearly) and by a less diminished extent of staining intensity in crypt-
associated cells. (i and j) The degree of inhibition was strongest for both forms of MGL so that the remaining staining intensity in surface
enterocytes of intestinal villi and crypt-associated cells was categorized as weak tomedium (for details on categories, please see legend to Fig. 6).
Concentration of biotinylated lectins usedwere 1 mgmL1 for DBA, 3 mgmL1 for SBA, 1.5 mg for HPA and 4 mgmL1 for the two engineered forms
of MGL. Scale bars are 20 mm.
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View Article Onlineand in the presence of compound 5 (Fig. S4d–f†). When adding
uorescein isothiocyanate (FITC)-labelled MGL to this binary
mixture, a solution containing three lectins is established.
Binding of each of these lectins to GalNAc-containing glyco-
conjugates can now be monitored independently at three wave-
lengths, and the eﬀect of presence of an inhibitor on each lectin
in the mixture is readily accessible.
The obtained results of this test case with the three lectins
using three-colour staining the tetravalent compound 5 as
inhibitor are presented in Fig. 8. Its panels show measure-
ments without/with inhibitor at each wavelength (Fig. 8a–c
and d–f) and the staining prole aer (photo)merging the
three individual les (Fig. 8g and h). Should it be the aim to
determine individual staining proles separately, in this
setting precluding competition among lectins for binding
sites, then processing of serial sections is advised. Here, the
inherent slight changes of spatial presentation of cellularThis journal is © The Royal Society of Chemistry 2018constituents, as given in Fig. S5,† needs to be taken into
account.
Using the test platform of the tissue sections with their
glycome complexity, any combination of lectins hereby
becomes amenable to assaying, that is proteins of the same
family and from diﬀerent families and especially tissue lectins
such as C-type lectins, galectins or siglecs. Since the distri-
butions of binding sites can well overlap when comparing this
property of activity between lectins, this assay is a means to
assess the extent of overlap, in itself biomedically relevant
information. The described uorescence microscopical
monitoring goes beyond measuring inhibition of lectin
binding to a glycoprotein. It facilitates detection of cell type-
dependent diﬀerences, thus extends in the tissue context
what array analysis with printed vesicles or cultured cells can
oﬀer.RSC Adv., 2018, 8, 28716–28735 | 28727
Fig. 8 Three-colour ﬂuorescence staining proﬁles by DBA, SBA and MGL (CRD + stalk) in longitudinal sections of ﬁxed murine jejunum in the
absence or presence of cognate sugar (GalNAc) presented by compound 5 and their (photo)merging. Accessible binding sites for the three
lectins were visualised by applying a mixture of biotinylated DBA, Alexa Fluor®-555-labelled SBA (colour assignment to blue) and FITC-labelled
MGL (CRD + stalk) (green). Localization of biotinylated DBA became detectable by the second-step reagent Alexa Fluor®-647-conjugated
streptavidin (5 mgmL1; colour assignment to red). DAPI was used for staining of nuclei (colour assignment to white). (a–c) Binding of DBA (a) and
SBA (b), respectively, was seen in the brush border (arrows) of intestinal enterocytes, in goblet cells (arrowheads) and crypt-associated cells
(asterisks). MGL binding was mainly conﬁned to the cytoplasm of surface enterocytes in intestinal villi (c). (d–f) No inhibition of DBA-dependent
staining (d) was seen with scaﬀold (compound 5)-presented GalNAc (0.1 mM), whereas binding of labelled SBA (e) and of MGL (f) was completely
inhibited. The three staining patterns were (photo)merged so that binding sites for each lectin in the same section were visualised in the absence
(g) and in the presence of cognate sugar (h). The regionally similar DBA- and SBA-dependent signal presence led to overlap (colour change to
magenta) in the brush border of intestinal villi, goblet cells and crypt-associated cells (g). No signiﬁcant overlap, in contrast, was seen with
labelled MGL (g). In the presence of compound 5 applied at 0.1 mM GalNAc, DBA-dependent staining was expectably rather insensitive to
inhibitor presence, when compared to SBA andMGL (h). Concentration of biotinylated DBAwas 1 mgmL1, that of Alexa Fluor®-555-labelled SBA
was 2 mg mL1 and FITC-labelled MGL was 16 mg mL1. DAPI was used at 0.5 mg mL1. Scale bars are 20 mm.
28728 | RSC Adv., 2018, 8, 28716–28735 This journal is © The Royal Society of Chemistry 2018
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View Article OnlineConclusions
In conclusion, the emerging broad signicance of pro-
tein(lectin)–glycan recognition is fueling the interest in devel-
oping glycoclusters as inhibitors of lectin binding. Since spatial
and structural parameters are being disclosed to matter for
achieving this type of functional pairing, the target of a thera-
peutic glycocluster, assaying of these synthetic products should
cover these factors of cellular glycomes to the highest possible
extent. Taking steps toward this aim is thus timely.
We here introduce a versatile platform for routine and
rigorously controlled application, i.e. tissue sections, and
illustrate the inuence of parameters on the side of glyco-
clusters (especially core structure and valency) and lectins,
especially architecture, ne-specicity and valency, on the
experimental read-out, and this on two cell populations. The
presented data strongly argue against the possibility for simple
extrapolations. The pertinent question on glycocluster activity
on lectins in mixtures, a common situation for tissue lectins, is
answered by uorescence microscopical monitoring using
diﬀerently labelled proteins.
Whereas chemical engineering of nanoparticle surfaces and of
cells programs tools for measuring inhibition of their bridging by
lectins,78–80 our assay examines all aspects of lectin binding. It
takes advantage of having cell and matrix glycomes available in
tissue sections, and their processing can for example ensure to
maintain glycolipid presence.81,82 In comparison to cultured cells,
the tissue ensures analysis of cells within their microenviron-
ment. This favourable aspect is also a part of the in vivo studies
with labelled neoglycoproteins presenting natural and synthetic
glycans up to custom-mademicroheterogeneity used for targeting
and imaging.83–89 On the side of the proteins, mimicking the
natural occurrence of lectins inmixtures, in terms of constituents
and relative concentrations, will enable to trace currently not well-
dened consequences of competition for binding sites and cross-
reactivity of glycoclusters among lectins. Given the assay's reli-
ability and sensitivity as well as its use with any type of tissue, its
application is advised, prior to considering testing glycoclusters in
vivo, for example to minimise such overlaps in target binding by
iterative structural renements including headgroup chemistry.
Experimental
General methods for synthesis
1H-NMR spectra were recorded (25 C) at 400 MHz or 500 MHz;
13C-NMR spectra were recorded at 100 MHz or 125 MHz.
Chemical shi (d) data in ppm are report with multiplicities
indicated as s (singlet), d (doublet), t (triplet), q (quartet), m
(multiplet); coupling constants (J) given in hertz (Hz). Chemical
shis (d) are reported relative to internal standard Me4Si in
CDCl3 (d 0.0) for
1H and CDCl3 (d 77.0) for
13C. 1H NMR spectral
signals were assigned with the aid of COSY, 13C NMR spectral
signals using DEPT, gHSQCAD and/or gHMBCAD. NMR spec-
troscopic data for known compounds was in good agreement
with those reported in the literature, as referenced. High reso-
lution ESI mass spectra were measured in positive and/or
negative mode using a Waters LCT Mass Spectrometer or wereThis journal is © The Royal Society of Chemistry 2018acquired using a microTOF-Q spectrometer interfaced to a Dio-
nex UltiMate 3000 LC in positive and negative modes as
required. MicroTof control 3.2 and HyStar 3.2 soware were
used to carry out the analysis for data obtained with the
microTOF-Q. TLC was performed on aluminium sheets pre-
coated with silica gel and spots visualized by UV and/or charring
with H2SO4–EtOH (1 : 20) or cerium molybdate, unless other-
wise stated. Chromatography was carried out with silica gel 60
(0.040–0.630 mm) and using a stepwise solvent polarity gradient
correlated with TLC mobility, unless otherwise stated. CH2Cl2,
MeOH, toluene and THF reaction solvents were used as ob-
tained from a Pure Solv™ Solvent Purication System. Unless it
is specied, all reagents were used as received without further
purication. All reactions involving air-sensitive reagents were
performed under nitrogen in oven-dried glassware using
syringe-septum cap technique. Optical rotations were deter-
mined at the sodium D line at 20 C using a Schmidt and
Haensch UniPol L1000. The IR spectra were recorded using thin
lm with a PerkinElmer Spectrum 100 FT-IR Spectrometer with
an ATR attachment.4-(1,2,2-Tris(4-(prop-2-yn-1-yloxy)phenyl)vinyl)phenyl acetate 11
To a solution of 10 (1.37 g, 3.45 mmol) at 0 C in pyridine (27.5
mL), Ac2O (228 mL, 2.41 mmol) was added over 2 h. The reaction
mixture was allowed to attain room temp and then stirred for
a further 3 h. The solvent was removed under diminished
pressure and chromatography (CH2Cl2–MeOH, 96.6 : 3.4) gave
the intermediate monoacetate (827 mg, 55%); 1H NMR (500
MHz, methanol-d4) d 6.99 (d, J¼ 8.8 Hz, 2H, o-Ar), 6.85–6.76 (m,
8H), 6.55–6.47 (m, 6H), 2.22 (s, 3H, OAc), 13C NMR (126 MHz,
methanol-d4) d ¼ 169.8(C, C]O), 155.6(C), 155.5 (C), 155.4 (C),
148.8 (C), 142.5 (C), 139.9 (C), 137.3 (C), 135.5 (C), 135.3 (C),
132.3 (CH), 132.2 (CH, 2), 132.0 (CH), 120.3 (CH), 114.1 (CH),
110.0 (C), 19.5(CH3, OAc); ESI-HRMS calcd for C28H21O5
437.1389, found m/z 437.1391 [M  H]. To this intermediate
(1.7 g, 3.9 mmol) in dry DMF (78 mL) was added anhydrous
potassium carbonate (6.42 g, 46.4 mmol); propargyl bromide
(80% in toluene, 2.72 mL, 31.0 mmol) was then added to the
mixture and it was stirred for 14 h at 70 C under an inert
atmosphere. The reaction was then cooled to room temp and
diluted with CH2Cl2 (300 mL) and was then washed with satd
NH4Cl. The aqueous layer was again washed with further
portions of CH2Cl2 (3  150 mL). The combined organic layers
were washed with water and dried over Na2SO4. The solvent was
removed under diminished pressure and column chromatog-
raphy (cyclohexane-EtOAc, 85 : 15 to 91 : 9) gave the title
compound (520 mg, 24%); 1H NMR (500 MHz, chloroform-d)
d 7.00 (d, J¼ 8.7 Hz, 2H,m-Ar), 6.96–6.91 (m, 6H, Ar), 6.83 (d, J¼
8.7 Hz, 2H, o-Ar), 6.74–6.68 (m, 6H, Ar), 4.61 (t, J ¼ 2.6 Hz, 6H,
CH2), 2.50 (t, J ¼ 2.5 Hz, 3H, propargylic), 2.25 (s, 3H, OAc),13C
NMR (126 MHz, chloroform-d) d ¼ 169.2(C, C]O), 156.1 (C),
156.1 (C), 156.0 (C), 148.9 (C), 141.6 (C), 139.5 (C), 138.2 (C),
137.1 (C), 137.0 (C), 137.0 (C), 132.5 (CH), 132.5 (CH), 132.3
(CH), 120.7 (CH), 114.1 (CH), 114.1(CH), 114.0(CH), 75.5 (CH),
75.4 (CH), 75.4 (CH), 55.8 (CH2, 2), 55.8 (CH2), 21.2 (CH3, OAc);
ESI-HRMS calcd for C37H28O5Na 575.1834, found m/z 575.1832RSC Adv., 2018, 8, 28716–28735 | 28729
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View Article Online[M + H]+. Note: the tetrapropargylated compound was the main
by-product as a result of partial deacetylation during the prop-
argylation reaction.4-(1,2,2-Tris(4-((1-(2-(2-deoxy-2-acetamido-D-
galactopyranosylthio)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)
phenyl)vinyl)phenol 3
To 11 (124 mg, 0.22 mmol) in degassed THF-H2O (1 : 1, 17.2 mL)
were added azide 12 (300 mg, 0.69 mmol), sodium ascorbate
(39 mg, 0.198 mmol) and Cu2SO4$5H2O (4942 mg, 0.198 mmol).
The reaction mixture was stirred under an inert atmosphere in
amicrowave reactor (120W) at 50 C for 30 min. Tetrahydrofuran
was then removed under diminished pressure followed by the
dilution with CH2Cl2. This mixture was then washed with water
and the aqueous layer was re-extracted with a further portion of
CH2Cl2. The combined organic layers were dried over Na2SO4 and
the solvent was removed under diminished pressure. Chroma-
tography of the residue (CH2Cl2–MeOH, 96.5 : 3.5 to 95.5 : 4.5)
gave the fully acetylated intermediate (411 mg, 70%) as a colour-
less solid; 1H NMR (500 MHz, chloroform-d) d 7.67 (s, 1H, triaz.),
7.67 (s, 1H, triaz.), 7.66 (s, 1H, triaz.), 7.00 (d, J ¼ 8.7 Hz, 2H, m-
Ar), 6.93–6.91 (m, 6H, Ar), 6.83 (d, J¼ 8.7 Hz, 2H, o-Ar), 6.73–6.68
(m, 6H, Ar), 5.97 (d, J ¼ 7.8 Hz, 1H, NH), 5.92 (d, J ¼ 8.1 Hz, 1H,
NH), 5.71 (d, J¼ 8.3 Hz, 1H, NH), 5.68–5.63 (m, 3H, H-1), 5.39 (dd,
J ¼ 3.2, 1.2 Hz, 3H, H-4), 5.14 (s, 2H, CH2), 5.14 (s, 2H, CH2), 5.13
(s, 2H, CH2), 5.01 (dt, J¼ 11.8, 3.3 Hz, 3H, H-3), 4.78–4.69 (m, 3H,
H-2), 4.65–4.55 (m, 6H, CH2), 4.52 (t, J ¼ 6.8 Hz, 3H, H-5), 4.20–
4.06 (m, 6H, CH2), 3.25–3.12 (m, 3H, CH2), 3.12–3.00 (m, 3H,
CH2), 2.25 (s, 3H, ArOAc), 2.16 (s, 3H, NHCH3), (s, 6H NHCH3),
2.01 (s, 3H, OAc), 2.00 (s, 6H, OAc), 1.99 (s, 6H, OAc), 1.99 (s, 3H,
OAc), 1.97 (s, 3H, OAc), 1.97 (s, 6H, OAc). To a suspension of this
intermediate (145mg, 0.078mmol), which was precooled to 0 C,
in dry methanol (7 mL), was added freshly prepared NaOMe
solution in MeOH until the solution pH was 9. The resulting
mixture was stirred for 2 h at room temp and then Amberlite IR-
120 H+, which had been washed with methanol, was added and
the mixture stirred gently for 10 min until the solution was
neutralized. The solution containing the product was separated
from the solid materials by decanting and the resin was washed
with a warmmixture of water-acetonitrile which was added to the
methanol solution. The volatile solvents were removed under
diminished pressure until a minimal amount of water remained.
Reverse phase column chromatography gave compound 3
(84 mg, 75%) as a colourless solid. 1H NMR (500 MHz, DMSO-d6)
d 9.33 (s, 1H, ArOH) 8.19 (s, 3H, triazo.), 7.80 (d, J ¼ 6.9 Hz, 3H,
NH), 6.85 (m, 6H, Ar), 6.79 (m, 6H, Ar), 6.73 (d, J¼ 8.4 Hz, 2H,m-
Ar), 6.51 (d, J ¼ 8.4 Hz, 2H, o-Ar), 5.51 (d, J1-2 ¼ 5.2 Hz, 3H, H-1),
5.02 (s, 6H, CH2), 4.80–4.65 (m, 12H,OH), 4.55 (ddt, J¼ 27.1, 13.9,
6.8 Hz, 6H,CH2), 4.16 (ddd, J2-3,2-NH,2-1 ¼ 11.8, 6.9,5.2 Hz, 3H, H-
2), 3.91 (t, J5-6,5-60 ¼ 6.0 Hz, 3H,H-5), 3.72 (brs, 3H, H-4), 3.53 (t, J6-
5,60-6 ¼ 5.9 Hz, 6H, H-6,H-60), 3.49 (dd, J3-2,3-4 ¼ 11.8, 2.9 Hz, 3H,
H-3), 3.02 (dt, J¼ 13.8, 6.9 Hz, 3H, CH2), 2.92 (dt, J¼ 13.7, 6.8 Hz,
3H), 1.79 (s, 9H, NHAc).13C NMR (126 MHz, dmso) d ¼ 170.3(C,
NHAc), 156.8 (C, Ar), 156.1 (C,m-Ar), 142.9 (C, triaz.), 142.8 (C),
139.0 (C), 137.1 (C), 132.5 (CH, m-Ar), 132.5 (CH,Ar), 125.2
(CH,triaz.), 114.4(CH, o-Ar), 114.3(CH, Ar), 84.8 (CH, H-1),28730 | RSC Adv., 2018, 8, 28716–2873572.7(CH, H-5), 68.5(CH, H-4), 67.9(CH, H-3), 61.3(CH2), 61.2
(CH2, C-6), 50.6(CH, C-2), 49.8 (CH2), 30.3(CH2), 23.1(CH3, NHAc);
ESI-HRMS calcd for C65H79 N12O19S3 1427.4747, found m/z
1427.4752 [MH]. Note: for the reverse phase chromatography,
a minimum volume of the aqueous residue was loaded onto the
column and elution involved passing three column volumes of
1 : 4 CH3CN–H2O followed by 1 : 1 CH3CN–H2O.
1,2,5,6-Tetra-O-(propargyl)-D-mannitol 14
Sodium hydride (1.0 g, 26.3 mmol, 60% in mineral oil) was added
to a cooled solution of 1332 (0.49 g, 2.2 mmol) in dry DMF (30 mL).
The suspension was stirred for 15 min and then 80% propargyl
bromide in toluene (2.9 mL, 26.3 mmol) was added. The resulting
mixture was stirred at room temp for 25 h, and aer this time
MeOH was added at 0 C. The mixture was diluted with EtOAc,
then washed with brine (3  20 mL), dried over Na2SO4, ltered
and the solvent was removed. Column chromatography (9 : 1
cyclohexane–EtOAc) gave the propargylated intermediate as
a yellow oil (0.77 g, 94%); [a]20D ¼ +6 (c 0.8, CHCl3); 1H NMR (500
MHz, CDCl3) d 4.38 (dd, 2H, Jgem ¼ 16.0 Hz, JH,H ¼ 2.4 Hz, CH2a-
C^CH-2), 4.35 (dd, 2H, Jgem¼ 16.0 Hz, JH,H¼ 2.4 Hz, CH2bC^CH-
2), 4.20 (dd, 2H, Jgem¼ 15.9 Hz, JH,H¼ 2.4 Hz, CH2aC^CH-1), 4.15
(dd, 2H, Jgem¼ 15.9Hz, JH,H¼ 2.4Hz, CH2bC^CH-1), 4.14 (dd, 2H,
J3,2¼ 3.6 Hz, J3,1 ¼ 1.5 Hz, H-3), 3.88 (dddd, 2H, J2,3 ¼ 3.6 Hz, J2,1b
¼ 6.3 Hz, J2,1a ¼ 3.2 Hz, JH,H ¼ 1.5 Hz, H-2), 3.84 (dd, 2H, J1a,1b ¼
10.6 Hz, J1a,2 ¼ 3.2 Hz, H-1a), 3.64 (dd, 2H, J1b,1a ¼ 10.6 Hz, J1b,2 ¼
6.3 Hz, H-1b), 2.44 (t, 2H, JH,H¼ 2.4 Hz, CH2C^CH-2), 2.42 (t, 2H,
JH,H¼ 2.4 Hz, CH2C^CH-1), 1.39 (s, 6H, CH3); 13C NMR (126MHz,
CDCl3) d 110.1 (C(CH3)2), 80.1 (CH2C^CH-2), 79.7 (CH2C^CH-1),
78.1 (C-2), 78.0 (C-3), 74.8 (CH2C^CH-1), 74.7 (CH2C^CH-2), 70.0
(C-1), 58.7 (CH2C^CH-1), 58.0 (CH2C^CH-2), 27.2 (CH3); ESI-
HRMS calcd for C21H26NaO6 397.1627, found: 397.1663 [M +
Na]+: hydrochloric acid (0.3 mL of 1.0 M) was added to this inter-
mediate (0.12 g, 0.32 mmol) in MeOH (2.7 mL). The resulting
mixture was heated at reux for 2.5 h and then allowed to attain
room temperature. Excess solid NaHCO3 was added and the
mixture stirred for a further 15 min. The solid was ltered oﬀ and
the solvent was evaporated and column chromatography (cyclo-
hexane–EtOAc, 7 : 3) gave 14 as a pale yellow oil (0.1 g, 94%); 1H
NMR (500 MHz, CDCl3) d 4.37 (dd, 2H, Jgem ¼ 16.0 Hz, JH,H ¼
2.4 Hz, CH2aC^CH-2), 4.32 (dd, 2H, Jgem¼ 16.0 Hz, JH,H¼ 2.4 Hz,
CH2bC^CH-2), 4.20 (d, 4H, JH,H ¼ 2.4 Hz, CH2C^CH-1), 3.91 (m,
2H, H-3), 3.88 (m, 2H, H-1a), 3.85 (m, 2H, H-2), 3.75 (dd, J1b,1a ¼
10.1 Hz, J1b,2¼ 4.8 Hz, 2H, H-1b), 2.84 (d, 2H, JOH,3¼ 6.2 Hz, OH),
2.46 (t, 2H, JH,H¼ 2.4 Hz, CH2C^CH-2), 2.45 (t, 2H, JH,H¼ 2.4 Hz,
CH2C^CH-1);
13C NMR (126 MHz, CDCl3) d 80.0 (CH2C^CH-2),
79.5 (CH2C^CH-1), 78.2 (C-2), 75.0 (CH2C^CH-1), 74.8
(CH2C^CH-2), 69.8 (C-1), 69.4 (C-3), 58.8 (CH2C^CH-1), 58.1
(CH2C^CH-2). ES-HRMS calcd for C18H22NaO6: 357.1314, found:
357.1295 [M + Na]+.
(2R,3S,4S,5R)-1,2,5,6-Tetrakis((1-(2-(2-deoxy-2-acetamido-a-D-
galactopyranosylthio)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-
hexane-3,4-diol 4 to 14
(0.16 g, 0.37 mmol) and 12 (43 mg, 0.13 mmol) in THF–H2O
(10 mL, 2 : 1), sodium ascorbate (26 mg, 0.13 mmol) andThis journal is © The Royal Society of Chemistry 2018
Paper RSC Advances
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
4 
A
ug
us
t 2
01
8.
 D
ow
nl
oa
de
d 
on
 1
1/
22
/2
01
9 
8:
01
:2
1 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article OnlineCuSO4$5H2O (33 mg, 0.13 mmol) were added. The resulting
mixture was stirred for 1.5 h at room temp. Aer this time, the
solvent was removed and the residue dissolved in CH2Cl2, then
washed with brine (2 10 mL), dried over Na2SO4, ltered and the
solvent was removed. Column chromatography of the residue
(CH2Cl2–MeOH, 15 : 1) gave the protected intermediate as a white
solid (0.11 g, 57%); [a]20D : +81 (c 1.1, CHCl3);
1H NMR (500 MHz,
CDCl3) d 7.79 (s, 2H, H-triazole 1), 7.78 (s, 2H, H-triazole 2), 6.82 (d,
2H, JNH,2 Gal¼ 7.6Hz, NH), 6.76 (d, 2H, JNH,2 Gal¼ 7.6 Hz, NH), 5.75
(d, 2H, J1,2 ¼ 4.6 Hz, H-1 Gal), 5.74 (d, 2H, J1,2 ¼ 4.6 Hz, H-1 Gal),
5.41 (s, 4H, H-4 Gal), 5.0 (dd, 2H, J3,2 ¼ 11.8 Hz, J3,4 ¼ 3.2 Hz, H-3
Gal), 4.99 (dd, 2H, J3,2¼ 11.8Hz, J3,4¼ 3.2Hz, H-3 Gal), 4.80 (d, 2H,
Jgem ¼ 12.8 Hz, CH2-triazole 2), 4.72 (m, 4H, H-2 Gal), 4.71 (d, 2H,
Jgem ¼ 12.8 Hz, CH2-triazole 2), 4.71 (d, 2H, Jgem ¼ 12.8 Hz, CH2-
triazole 1), 4.62 (d, 2H, Jgem¼ 12.8 Hz, CH2-triazole 1), 4.61 (m, 8H,
SCH2CH2), 4.55 (dd, 4H, J5,6b¼ 7.0 Hz, J5,6a¼ 5.4 Hz, H-5 Gal), 4.15
(dd, 4H, J6a,6b ¼ 11.3 Hz, J6a,5 ¼ 5.4 Hz, H-6a Gal), 4.09 (dd, 4H,
J6b,6a ¼ 11.3 Hz, J6b,5 ¼ 7.0 Hz, H-6b Gal), 3.87 (dd, 2H, J3,2 ¼ J3,OH
¼ 6.4 Hz, H-3), 3.80 (m, 2H, H-1a), 3.71 (m, 2H, H-2), 3.69 (m, 2H,
H-1b), 3.65 (d, 2H, JOH,3 ¼ 6.4 Hz, OH), 3.18 (m, 4H, SCH2aCH2),
3.08 (m, 4H, SCH2bCH2), 2.16 (s, 12H), 2.0 (s, 6H), 1.99 (s, 6H), 1.99
(s, 12H), 1.98 (s, 6H) (each OCOCH3), 1.98 (s, 6H, NHCOCH3);
13C
NMR (126 MHz, CDCl3) d 171.1, 171.1 (each NHCOCH3), 170.9,
170.9, 170.6, 170.6, 170.4, 170.4 (each OCOCH3), 145.3 (C-4
triazole-2), 145.0 (C-4 triazole-1), 123.7 (2) (C-5 triazole-1, C-5
triazole-2), 85.2, 84.9 (each C-1 Gal), 78.6 (C-2), 70.0 (C-1), 68.9
(C-3), 68.3 (2) (C-3 Gal), 67.5 (2) (C-5 Gal), 67.2 (2) (C-4 Gal),
64.7 (CH2-triazole 1), 63.7 (CH2-triazole 2), 62.2, 62.2 (each C-6 Gal),
49.8, 49.6 (each SCH2CH2), 48.4 (2) (C-2 Gal), 31.3, 31.2 (each
SCH2CH2), 23.2 (2) (NHCOCH3), 20.9, 20.9, 20.8 (2), 20.8 (2)
(each OCOCH3); ESI-HRMS calcd for C82H118N16NaO38S4:
2085.6574, found: 2085.6567 [M + Na]+. To this protected inter-
mediate (42 mg, 0.02 mmol) in dry MeOH (2 mL), freshly prepared
NaOMe solution in MeOH (0.35 mL of 1 M) was added and the
mixture was stirred at room temp for 4 h. Then Amberlite IR-120
H+ was added and stirred gently until the pH was 7. The resin
was ltered oﬀ and the solvent was removed. Reverse phase
column chromatography (MeCN–H2O, 0 : 1 to 1 : 1) gave the title
compound 4 as a white solid (24 mg, 76%); [a]20D : +106 (c 0.8,
DMSO); 1H NMR (500 MHz, DMSO-d6) d 8.10 (d, 2H, H-triazole 1),
8.0 (d, 2H, H-triazole 2), 7.77 (d, 4H, JNH,2 Gal¼ 6.5 Hz, NH), 5.51 (d,
4H, J1,2 ¼ 5.1 Hz, H-1 Gal), 4.70 (m, 6H, OH, CH2-triazole 2), 4.68
(m, 4H, OH), 4.61 (m, 2H, OH), 4.58 (m, 6H, CH2-triazole 2, OH),
4.56 (m, 4H, CH2-triazole 1), 4.53 (m, 8H, (SCH2CH2), 4.19 (ddd,
4H, J2,3 ¼ 11.8 Hz, J2,NH ¼ 6.5 Hz, J2,1 ¼ 5.1 Hz, H-2 Gal), 3.92 (m,
4H,H-5 Gal), 3.85 (m, 2H, H-1a), 3.73 (m, 4H,H-4Gal), 3.60 (m, 4H,
H-2, H-3), 3.58 (m, 2H, H-1b), 3.55 (m, 8H, H-6 Gal), 3.50 (m, 4H, H-
3 Gal), 3.02 (m, 4H, SCH2aCH2), 2.93 (m, 4H, SCH2bCH2), 1.81 (s,
6H), 1.80 (s, 6H) (each NHCOCH3).
13C NMR (126 MHz, DMSO-d6)
d 169.9, 169.9 (NHCOCH3), 144.4 (C-4 triazole-2), 144.0 (C-4
triazole-1), 124.0 (C-5 triazole-1), 123.8 (C-5 triazole-2), 84.4 (2)
(C-1 Gal), 78.1 (C-2), 72.2, 72.2 (each C-5 Gal), 71.1 (C-1), 68.1 (3)
(C-4 Gal, C-3), 67.5 (2) (C-3 Gal), 64.0 (CH2-triazole 1), 63.4 (CH2-
triazole 2), 60.9, 60.9 (each C-6 Gal), 50.0 (2) (C-2 Gal), 49.3 (2)
(SCH2CH2), 29.9, 29.8 (each SCH2CH2), 22.7 (2) (NHCOCH3). ESI-
HRMS calcd for C58H94N16NaO26S4: 1581.5306, found: 1581.5365
[M + Na]+.This journal is © The Royal Society of Chemistry 2018BF2 chelated 3-methyl-N-(3-methyl-5-(4-(prop-2-yn-1-yloxy)
phenyl)-1H-pyrrol-2-yl)-5-(4-(prop-2-yn-1-yloxy)phenyl)-2H-
pyrrol-2-imine 16
To 1534 (500 mg, 1.35 mmol) in dry CH2Cl2 (20 mL) at78 C, was
added dropwise BBr3 (1 M in CH2Cl2, 5.4 mmol) and the mixture
stirred at 78 C for 3 h. The reaction mixture was quenched by
the slow addition of saturated sodium bicarbonate (30 mL), the
organic layer was then separated and the aqueous layer was
extracted with CH2Cl2 (2  40 mL). The combined organic layers
were washed with saturated sodium bicarbonate, deionized H2O,
brine, dried over Na2SO4, ltered, and the solvent was removed
under reduced pressure. Silica gel chromatography (cyclohexane–
EtOAc, 3 : 1) gave the demethylated intermediate as a dark blue
solid (169 mg, 35%, mp 121–122 C); 1H NMR (400 MHz, CD3OD-
d4): d 7.72 (dd, J ¼ 8.8, 1.9 Hz, 4H), 6.89 (dd, J ¼ 8.8, 1.9 Hz, 4H),
6.71 (s, 2H), 4.57 (br, 2H), 2.26 (s, 6H) ppm; 13C NMR (100 MHz,
CD3OD-d4): d 159.4, 154.4, 150.6, 140.3, 127.7, 123.8, 115.7, 115.7,
9.9 ppm; ESI-HRMS [M + H]+: 358.1541, C22H20N3O2 requires
358.1556. To this intermediate (160mg, 0.45mmol) in dry THF (25
mL) cesium carbonate (439 mg, 1.35 mmol) was added, and the
mixture was stirred at 0 C under a nitrogen atmosphere for
10 min. Propargyl p-toluenesulfonate (473 mg, 2.25 mmol) was
then added via syringe and the solutionwas heated at reux, whilst
stirring, for 2 h. The reaction mixture was cooled to room temp
and themixture was partitioned betweenCH2Cl2 (100mL) and PBS
buﬀer (100 mL, pH 7). The organic phase was washed with water
(3  100 mL), brine (50 mL), dried over Na2SO4, ltered and
evaporated to dryness. The crude product was puried by silica gel
chromatography, eluting with CH2Cl2 to yield the propargylated
intermediate compound (107 mg, 55%, mp 133–135 C) as a dark
green solid; 1H NMR (400 MHz, CDCl3): d 7.80 (d, J ¼ 7.5 Hz, 1H),
7.08 (d, J ¼ 7.4 Hz, 1H), 6.66 (s, 1H), 4.78 (s, 1H), 2.57 (s, 1H), 2.34
(s, 2H) ppm. 13C NMR (100 MHz, CDCl3): d 158.7, 154.0, 150.0,
141.0, 127.8, 126.2, 116.3, 115.4, 78.2, 76.0, 55.9, 11.4 ppm; ESI-
HRMS calcd for C28H24N3O2 434.1869, found m/z 434.1869 [M +
H]+.To this intermediate (100 mg, 0.23 mmol) in dry CH2Cl2 (20
mL) DIPEA (0.4 mL, 2.3 mmol) was added and BF3$OEt2 (0.4 mL,
3.22 mmol), and the mixture was stirred at room tem under N2 for
20 h. The reaction mixture was washed with water (3  50 mL),
brine, dried over Na2SO4, ltered and the solvent was removed
under reduced pressure. Chromatography (cyclohexane–EtOAc,
4 : 1) gave the title compound 16 as red metallic solid (67 mg,
61%); 1HNMR (400MHz, DMSO-d6): d 8.05 (d, J¼ 9.0 Hz, 4H), 7.14
(d, J¼ 9.0 Hz, 4H), 7.01 (s, 2H), 4.93 (d, J¼ 2.4 Hz, 4H), 3.65 (t, J¼
2.4 Hz, 2H), 2.33 (s, 6H) ppm; 13C NMR (100 MHz, DMSO-d6):
d 160.0, 157.8, 146.0, 143.3, 131.8, 124.3, 122.6, 115.6, 79.3, 79.2,
56.2, 11.6 ppm; ESI-HRMS calcd for C28H23BF2N3O2 482.1851,
found m/z 482.1849 [M + H]+.3-Methyl-N-(3-methyl-5-(4-((1-(2-(2-acetamido-2-deoxy-a-D-
galactopyranosylthio)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)
phenyl)-2H-pyrrol-2-ylidene)-5-(4-((1-(2-(2-acetamido-2-deoxy-
a-D-galactopyranosylthio)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)
phenyl)-1H-pyrrol-2-amine, BF2 chelate 6
Compound 16 (5.1 mg, 0.0168 mmol) was dissolved in H2O (1
mL) and de-O-acetylated 12 (3.7 mg, 7.7 mmol), prepared asRSC Adv., 2018, 8, 28716–28735 | 28731
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View Article Onlinedescribed for 7 (below) from 12, was dissolved in THF (1 mL)
and both solutions were added to a microwave vial and to this
sodium ascorbate (7.65 mg, 0.0386 mmol) and copper sulphate
pentahydrate (4.19 mg, 0.0168 mmol) were added. The mixture
was heated in a microwave reactor (120 W) at 60 C, for 1 h. The
THF was then removed under vaccum and the remaining water
was diluted with CH3CN and reverse phase chromatography
(H2O–CH3CN, 1 : 1) gave the title compound 6 as a green solid
(5.4 mg, 64%); 1H NMR (500 MHz, DMSO-d6) d 8.21 (s, 2H, tri-
azole CH), 8.03–7.98 (m, 4H, Ar–H), 7.70 (d, J ¼ 7.0 Hz, 2H, NH),
7.18–7.11 (m, 4H), 6.97 (s, 2H, Ar–H), 5.46 (d, J ¼ 5.3 Hz, 2H, H-
1), 5.21 (s, 4H, CH2OAr), 4.68–4.61 (m, 4H, OH-4, OH-6), 4.60–
4.45 (m, 6H, SCH2CH2, OH-3), 4.13 (dt, J ¼ 11.9, 6.3 Hz, 2H, H-
2), 3.87 (t, J ¼ 6.0 Hz, 2H, H-5), 3.68 (t, J ¼ 4.0 Hz, 2H, H-4), 3.50
(t, J ¼ 5.8 Hz, 4H, H-6), 3.44 (ddd, J ¼ 10.8, 6.7, 3.0 Hz, 2H. H-3),
3.00 (dt, J¼ 14.0, 6.9 Hz, 2H SCH2CH2), 2.90 (dt, J¼ 13.9, 6.9 Hz,
2H, SCH2CH2), 2.28 (s, 6H, CH3), 1.76 (d, J ¼ 1.4 Hz, 6H, NHAc);
13C NMR (126 MHz, dmso) d 170.21 (C]O), 160.95, 157.70,
155.31, 145.95, 143.04, 142.42 (C), 131.91 (CH), 125.45 (triazole
CH), 123.91, 115.48 (each Ar-CH), 84.77 (C-1), 72.67 (C-5), 68.53
(C-4), 67.91 (C-3), 61.85 (CH2OAr), 61.34 (C-6), 50.43 (C-2), 49.79
(SCH2CH2), 30.27 (SCH2CH2), 23.06 (NHAc), 11.49 (CH3); ESI-
HRMS: calcd for C48H58BN11O12 F2S2 Na 1116.3667; found
1116.3676 [M + Na]+Methyl 2-acetamido-2-deoxy-1-thio-a-D-galactopyranoside 7
The thiol 1635 (77 mg, 0.199 mmol) was dissolved in
dichloromethane (3 mL) and DIPEA (0.4 mmol, 70 mL) and
methyl iodide (0.9 mmol, 56 mL) was added and the mixture
was stirred for 2.5 h at room temp. The solvent was removed
and ash chromatography (toluene–acetone (6 : 4)) gave the
protected intermediate (62 mg, 82%); 1H NMR (500 MHz,
chloroform-d) d 5.64 (d, J ¼ 8.8 Hz, 1H, NH), 5.44 (d, J ¼
5.3 Hz, 1H, H-1), 5.38 (dd, J ¼ 3.3, 1.3 Hz, 1H, H-4), 5.09 (dd, J
¼ 11.7, 3.3 Hz, 1H, H-3), 4.80–4.74 (m, 1H, H-2), 4.55–4.50
(m, 1H, H-5), 4.17–4.06 (m, 2H, H-6), 2.16 (s, 3H, OAc), 2.12
(s, 3H, CH3), 2.04 (s, 3H, OAc), 2.00 (s, 3H, OAc), 1.97 (s, 3H,
NHAc); 13C NMR (126 MHz, CDCl3) d 171.06, 170.37, 170.26,
170.15(each C]O), 85.53 (C-1), 68.44 (C-3), 67.35 (C-4), 67.11
(C-5), 61.92 (C-6), 48.38 (C-2), 23.30 (NHAc), 20.74, 20.69,
20.68 (each OAc), 13.15 (CH3). To this intermediate (55 mg,
0.14 mmol) dissolved in MeOH (2 mL) was added 1 M NaOMe
in MeOH and the mixture was le to stir until the pH was10
and stirring was continued for 20 min. Amberlite H+ resin
was then added until the pH was 6 and was stirred for
another 20 min. The mixture was then ltered and solvent
removed under reduced pressure to give the title compound
as a white solid (25 mg, 70%); 1H NMR (500 MHz, methanol-
d4) d 5.44 (d, J ¼ 5.4 Hz, 1H, H-1), 4.41 (dd, J ¼ 11.2, 5.4 Hz,
1H, H-2), 4.14 (ddd, J ¼ 6.7, 5.2, 1.3 Hz, 1H, H-5), 3.88 (dd, J ¼
3.3, 1.4 Hz, 1H, H-4), 3.76–3.70 (m, 3H, H-3, H-6a, H-6b), 2.06
(s, 3H, CH3), 1.96 (s, 3H, NHAc);
13C NMR (126 MHz, meth-
anol-d4) d 172.51 (C]O), 84.82 (C-1), 71.29 (C-5), 68.91 (C-4),
68.08 (C-3), 61.38 (C-6), 50.55 (C-2), 21.14 (NHAc), 11.55
(CH3); ESI-HRMS calcd for C9H17NO5SNa 274.0725, found
m/z 274.0729 [M + Na]+.28732 | RSC Adv., 2018, 8, 28716–287352-Azidoethyl 2-acetamido-2-deoxy-1-thio-a-D-glucopyranoside 18
Thioglycoside 17 (40 mg, 0.092 mmol) was deacetylated as
described in the preparation of 7 to give the title compound
(24 mg, 85%); 1H NMR (500 MHz, methanol-d4) d 5.56 (d, J ¼
5.3 Hz, 1H, H-1), 4.03 (dd, J¼ 11.1, 5.3 Hz, 1H, H-2), 3.96 (ddd, J¼
10.0, 5.8, 2.4 Hz, 1H, H-5), 3.83 (dd, J¼ 12.0, 2.3 Hz, 1H, H-6a), 3.71
(dd, J¼ 12.0, 5.8 Hz, 1H, H-6b), 3.58 (dd, J¼ 11.1, 8.7 Hz, 1H, H-3),
3.55–3.49 (m, 1H, SCH2CH2N3), 3.45 (dt, J ¼ 12.8, 6.7 Hz, 1H,
SCH2CH2N3), 3.37–3.31 (m, 1H, H-4), 2.89–2.81 (m, 1H, SCH2-
CH2N3), 2.73 (dt, J ¼ 13.7, 6.6 Hz, 1H, SCH2CH2N3), 1.97 (s, 3H,
NHAc); 13C NMR (126 MHz, methanol-d4) d 172.31 (C]O), 83.98
(C-1), 73.05 (C-5), 71.19 (C-3), 71.08 (C-4), 61.20 (C-6), 54.41 (C-2),
50.78 (SCH2CH2N3), 29.77 (SCH2CH2N3), 21.12 (NHAc); ESI-
HRMS: calcd. For C10H19N4O5S 307.1076; found 307.1070 [M +H]
+.3-Phenyl-N-(3-phenyl-5-(4-((1-(2-(2-acetamido-2-deoxy-a-D-
glucoopyranosylthio)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)
phenyl)-2H-pyrrol-2-ylidene)-5-(4-((1-(2-(2-acetamido-2-deoxy-
a-D-glucopyranosylthio)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)
phenyl)-1H-pyrrol-2-amine, BF2 chelate 8
Glucopyranoside 18 (5.56 mg, 0.0181 mmol) in H2O (1 mL) and
1933 (5 mg, 0.082 mmol) in THF (1 mL) were mixed and added to
a microwave vial and to this mixture sodium ascorbate (8.2 mg,
0.041 mmol) and copper sulphate pentahydrate (8.2 mg, 0.041
mmol) were added. The reaction was performed in themicrowave
(120 W) at 60 C for 1 h. The THF was then removed under
vacuum to concentrate the mixture with some water remaining.
This was diluted with CH3CN and reverse phase chromato-
graphy (H2O–CH3CN, 1 : 1) gave 8 as a green solid (8.6 mg, 86%);
1H NMR (500MHz, DMSO-d6) d 8.29 (s, 2H, triazole CH), 8.19 (dd,
J ¼ 11.3, 8.1 Hz, 7H, Ar–H), 7.87 (d, J ¼ 7.0 Hz, 2H, NH), 7.64 (s,
2H, Ar–H), 7.55 (t, J ¼ 7.6 Hz, 4H, Ar–H), 7.49 (t, J ¼ 7.3 Hz, 2H,
Ar–H), 7.26 (dd, J ¼ 7.9, 5.5 Hz, 4H, Ar–H), 7.19–7.14 (m, 1H, Ar–
H), 5.47 (d, J¼ 5.3 Hz, 2H, H-1), 5.30 (s, 4H, CH2OAr), 5.15 (d, J¼
5.6 Hz, 2H, 4-OH), 4.85 (d, J ¼ 5.7 Hz, 2H, 3-OH), 4.68 (t, J ¼
5.7 Hz, 2H, 6-OH), 4.58 (ddt, J ¼ 27.7, 13.9, 7.0 Hz, 4H, SCH2CH2
triazole), 3.81 (ddd, J ¼ 11.8, 6.9, 5.3 Hz, 2H, H-2), 3.78–3.68 (m,
4H, H-5, H-6a), 3.51 (dt, J¼ 11.9, 6.2 Hz, 2H, H-6b), 3.41–3.35 (m,
2H, H-3), 3.18–3.04 (m, 4H, H-4, SCH2CH2), 3.00 (dt, J ¼ 13.7,
6.8 Hz, 2H, SCH2CH2), 1.83 (s, 6H, NHAc);
13C NMR (126 MHz,
dmso) d 170.07 (C]O), 170.07 (C]O), 161.27, 157.84, 148.14,
145.00, 142.46, 142.60 (each Ar–C), 132.27, 130.05, 129.58, 129.35,
129.17, 128.65 (each Ar–H), 125.45, 123.93, 115.60 (each Ar–H),
84.49 (C-1), 74.21(C-5), 71.42 (C-4), 71.08 (C-3), 61.96 (CH2OAr),
61.34 (C-6), 54.63 (C-2), 49.82 (SCH2CH2), 30.56 (SCH2CH2), 23.05
(NHAc); ESI-HRMS: calcd for C58H62BN11O12F2S2Na 1240.3980;
found 1240.3395 [M + Na]+.Lectins
The two recombinant MGL proteins (CRD and CRD extended by
the stalk) were produced, puried and subjected to quality controls
as described in detail previously.31 SBAwas purchased from Sigma-
Aldrich (Munich, Germany). Biotinylated DBA was obtained from
Enzo Life Sciences (Lo¨rrach, Germany), biotinylated HPA from
Sigma-Aldrich. Biotinylation of the MGL proteins and SBA wasThis journal is © The Royal Society of Chemistry 2018
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View Article Onlineperformed under activity-preserving conditions with the N-
hydroxysuccinimide ester derivative of biotin (Sigma-Aldrich)
using the protocol used for human galectin-1.83,90 Fluorescent
labeling was performed using the Alexa Fluor® 555 or the Alexa
Fluor® 488 Protein Labeling Kits (Molecular Probes, Thermo
Fisher Scientic, Darmstadt, Germany) following the recommen-
dations of the supplier. Maintained lectin activity was ascertained
by carbohydrate-inhibitable cell binding in cytouorometric assays
using CHO wild-type and Lec8 mutant cells31,84,91 and in the
histochemical protocol (please see below).
Tissue samples
Specimens of jejunum obtained from four six-week-old C57BL/6
mice were thoroughly washed, then cut into small pieces and
xed in Bouin's solution (71% (v/v) saturated picric acid, 24% (v/
v) formaldehyde solution (37% w/v) and 5% (v/v) glacial acetic
acid) for 24 h. Dehydration of specimens was carried out in
a series of aqueous ethanol solutions of increasing alcohol
concentrations (70%, 80% and 99%) and then in isopropanol,
which nally was replaced by xylene. Embedding of the pieces of
tissue in paraﬃn wax at 61 C followed, thereaer each spe-
cimen was cut into serial sections of about ve mm thickness
that were mounted on Superfrost® plus glass slides (Menzel,
Braunschweig, Germany). Tissue specimen of murine jejunum
were a kind gi of Dr E. Wolf of the Faculty of Veterinary
Medicine, Ludwig-Maximilians-University Munich, Germany;
all further processing was done by the authors as described.
Lectin histochemistry
The protocols for processing tissue sections by lectin histochem-
istry and monitoring staining proles by light and uorescence
microscopy had been optimized previously.69,85,92,93 Routinely,
systematic titrations with each labelled lectin were carried out to
determine the concentrations, which generate strong signals
combined with minimal background staining. The tested
concentration ranges for light/uorescence microscopy were 0.25–
1.5/0.5–1 mgmL1 for DBA, 0.5–4/0.25–4 mgmL1 for SBA, 0.5–2/1–
2 mg mL1 for HPA, 1–8 mg mL1 for MGL (CRD) and 1–8/8–32 mg
mL1 forMGL (CRD + stalk), respectively. Assessment of inhibitory
capacity of glycocompounds was determined aer a pre-
incubation of the mixture containing a glycocompound and lec-
tin for one hour at room temperature. Aliquots of these mixtures
were then applied to deparaﬃnized tissue sections for an over-
night incubation at 4 C. The processing of sections used for light
or uorescence microscopy diﬀered slightly.
When running the protocol for light microscopy, sections
had been washed in 10 mM 4-(2-hydroxyethyl)-1-piperazine-
ethanesulfonic acid buﬀer (HEPES, pH 7.5) containing
0.1 mM CaCl2 and then treated with this buﬀer containing 1%
(w/v) carbohydrate-free bovine serum albumin (BSA), for 1 h at
room temperature to saturate sites for non-specic binding of
proteins. Following washing steps and aer the incubation with
lectin-containing solution in the absence/presence of glyco-
inhibitors, visualisation of signals was accomplished by
applying commercial Vectastain® ABC kit and Vector Red®
reagents (Biozol, Eching, Germany).This journal is © The Royal Society of Chemistry 2018The route to obtaining proles of uorescent staining started
by incubating deparaﬃnized sections in a humid chamber with
a 1% (w/v) solution of BSA in HEPES buﬀer containing 0.1 mM
CaCl2 and 0.1% (w/v) Tween-20 (blocking solution) to saturate
non-specic binding of protein. Subsequently, sections were
exposed to labelled lectins dissolved in blocking solution, e.g.
Alexa Fluor®-555-labelled SBA, biotinylated DBA or HPA, or
a ternary mixture containing the uorescent SBA, biotinylated
DBA and FITC-labelled MGL (CRD + stalk), in a humid chamber
overnight at 4 C. Aer two thorough washing steps (each for 5
min) in HEPES buﬀer/Tween 20 and a washing step in PBS/
Tween-20 (PBS-T) to remove the labelled probes, Alexa Fluor®-
647-conjugated streptavidin (Invitrogen, Thermo Fisher
Sciences, Darmstadt, Germany) (solutions of 2–10 mg mL1 were
tested, 5 mg mL1 was found to be optimal) in 1% BSA/PBS-T
was applied for 1 h, then 40,6-diamidino-2-phenylindole
(DAPI; 0.5 mg mL1) in PBS-T was added for 5 min at room
temperature in a humid chamber in the dark.
Processed sections for light microscopy were counterstained
with Mayer's haemalaun, dehydrated and mounted with Eukitt®
(Kindler, Freiburg, Germany). For uorescence microscopy,
a mounting medium containing an anti-fading agent (Dako
Fluorescence Mounting Medium; Agilent DAKO, Waldbronn,
Germany) was used. Controls to exclude lectin-independent
staining were performed by omission of the incubation step
with lectin-containing solution. Controls of sugar specicity were
carried out by using the cognate sugar in titrations. Lack of
inhibition by carbohydrate-independent binding of the bulky
scaﬀolds in bivalent compound 6 and tetravalent compound 5 by
comparing the activity of GalNAc-presenting compounds 5 and 6
to interfere with lectin binding in parallel with testing the cor-
responding GlcNAc-presenting compounds 8 and 9 (0.05–2 mM
of sugar) on MGL (CRD + stalk) and SBA.
Microphotographs were recorded using an AxioImager.M1
microscope (Carl Zeiss MicroImaging, Go¨ttingen, Germany)
equipped with an AxioCam MRm digital camera and the soware
AxioVision version 4.9. Semi-quantitative analysis by two inde-
pendent observers was based on independently examining at least
ten high-power elds per section. Signal intensity is expressed in
the following grading system: , no staining; (+), very weak but
signicant staining; +, weak staining; ++, medium staining; +++,
strong staining; ++++, very strong staining. The percentage of
positive cells is grouped in the categories: (1) 0% (no positive cells),
(2) < 5% (few positive cells), (3) 5–20%, (4) 21–40%, (5) 41–60%, (6)
61–80%, (7) 81–95% (few negative cells), (8) up to 100% (no
negative cells).Conﬂicts of interest
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